Bergen, Norway, 3 September 2019 - Reference is made to the stock exchange
notice published by BerGenBio ASA (the "Company") (OSE: BGBIO) on 28 August 2019
where the Company announced that the board of directors of the Company had
resolved to increase the Company's share capital in connection with the exercise
options pursuant to the Company's share option program. A total of 540,000
options were exercised at an average subscription price of NOK 8.39 per share.
The share capital increase has been duly registered in the Norwegian Register of
Business Enterprises. Following such registration, the Company's share capital
is NOK 6,107,659 divided into 61,076,590 shares, each with a nominal value of
NOK 0.10.

-End-

Contacts

Richard Godfrey
CEO, BerGenBio ASA
+47 917 86 304

Rune Skeie
CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

Forward looking statements

This announcement may contain forward-looking statements, which as such are
not historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.